Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + ixabepilone
- Development stage
- Phase 3
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This regimen is a combination chemotherapy protocol consisting of cyclophosphamide, doxorubicin, and ixabepilone. Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell death. Doxorubicin is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, preventing DNA replication and repair. Ixabepilone is a microtubule stabilizer (an epothilone B analog) that binds to β-tubulin subunits in microtubules, promoting their stabilization and inhibiting mitosis. This combination has been studied primarily as neoadjuvant or adjuvant therapy for early-stage or triple-negative breast cancer, especially in patients with resistance to taxanes or anthracyclines[1][2][3]. The regimen aims to exploit the complementary mechanisms of action of each drug for enhanced antitumor efficacy.
- Brand names
- Adriamycin (doxorubicin)Ixempra (ixabepilone)
- Other names
- AC + ixabepilone
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + ixabepilone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + ixabepilone.